{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:42:26Z","timestamp":1758814946045,"version":"3.44.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"DOI":"10.1007\/s10840-025-02014-x","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:23:23Z","timestamp":1739219003000},"page":"897-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of SGLT2 inhibitor on clinical and echocardiographic outcomes in patients with CRT during long-term period"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-4142","authenticated-orcid":false,"given":"Tariel A.","family":"Atabekov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey N.","family":"Krivolapov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina K.","family":"Silivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail S.","family":"Khlynin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina V.","family":"Kisteneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman E.","family":"Batalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey V.","family":"Popov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"6","key":"2014_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/eurjhf\/hfs055","volume":"14","author":"JG Cleland","year":"2012","unstructured":"Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012;14(6):628\u201334.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2014_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325.","journal-title":"Circulation"},{"issue":"3","key":"2014_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2014_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","volume":"142","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Jhund PS, Anand I, et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142(17):1623\u201332.","journal-title":"Circulation"},{"issue":"36","key":"2014_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"6","key":"2014_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.amjcard.2010.11.010","volume":"107","author":"DG Strauss","year":"2011","unstructured":"Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol. 2011;107(6):927\u201334.","journal-title":"Am J Cardiol"},{"issue":"35","key":"2014_CR7","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"M Glikson","year":"2021","unstructured":"Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427\u2013520.","journal-title":"Eur Heart J"},{"issue":"1","key":"2014_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s43044-022-00308-3","volume":"74","author":"KA Shoman","year":"2022","unstructured":"Shoman KA, Eldamanhory HM, Fakhry EE, Badran HA. Role of Strauss ECG criteria as predictor of response in patients undergoing cardiac resynchronization therapy. Egypt Heart J. 2022;74(1):69.","journal-title":"Egypt Heart J"},{"key":"2014_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1253\/circj.CJ-10-1268","volume":"75","author":"A Auricchio","year":"2011","unstructured":"Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J. 2011;75:521\u20137.","journal-title":"Circ J"},{"issue":"1","key":"2014_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10741-018-9734-8","volume":"24","author":"BJ Sieniewicz","year":"2019","unstructured":"Sieniewicz BJ, Gould J, Porter B, et al. Understanding non-response to cardiac resynchronization therapy: common problems and potential solutions. Heart Fail Rev. 2019;24(1):41\u201354.","journal-title":"Heart Fail Rev"},{"key":"2014_CR11","doi-asserted-by":"publisher","first-page":"131391","DOI":"10.1016\/j.ijcard.2023.131391","volume":"393","author":"C Fonderico","year":"2023","unstructured":"Fonderico C, Pergola V, Faccenda D, et al. Impact of sacubitril\/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients. Int J Cardiol. 2023;393:131391.","journal-title":"Int J Cardiol"},{"key":"2014_CR12","doi-asserted-by":"crossref","unstructured":"Pires LA, Abraham WT, Young JB, Johnson KM; MIRACLE and MIRACLE-ICD Investigators. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. Am Heart J 2006;151(4):837\u201343.","DOI":"10.1016\/j.ahj.2005.06.024"},{"issue":"3","key":"2014_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2019.02.027","volume":"74","author":"PS Douglas","year":"2019","unstructured":"Douglas PS, Carabello BA, Lang RM, et al. 2019 ACC\/AHA\/ASE key data elements and definitions for transthoracic echocardiography: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards) and the American Society of Echocardiography. J Am Coll Cardiol. 2019;74(3):403\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"2014_CR14","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.hrthm.2019.02.034","volume":"17","author":"MK Stiles","year":"2020","unstructured":"Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS\/EHRA\/APHRS\/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2020;17:e220\u20138.","journal-title":"Heart Rhythm"},{"issue":"21","key":"2014_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"7","key":"2014_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","volume":"6","author":"M Omar","year":"2021","unstructured":"Omar M, Jensen J, Ali M, et al. Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF randomized clinical trial. JAMA Cardiol. 2021;6(7):836\u201340.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2014_CR17","doi-asserted-by":"publisher","first-page":"18025","DOI":"10.1038\/s41598-023-45390-y","volume":"13","author":"R Kawakami","year":"2023","unstructured":"Kawakami R, Matsui H, Matsui M, et al. Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice. Sci Rep. 2023;13(1):18025.","journal-title":"Sci Rep"},{"issue":"1","key":"2014_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10840-018-0363-x","volume":"52","author":"J Garcia-Seara","year":"2018","unstructured":"Garcia-Seara J, Iglesias Alvarez D, Alvarez Alvarez B, et al. Cardiac resynchronization therapy response in heart failure patients with different subtypes of true left bundle branch block. J Interv Card Electrophysiol. 2018;52(1):91\u2013101.","journal-title":"J Interv Card Electrophysiol"},{"key":"2014_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijcard.2018.07.060","volume":"269","author":"ML Caputo","year":"2018","unstructured":"Caputo ML, van Stipdonk A, Illner A, et al. The definition of left bundle branch block influences the response to cardiac resynchronization therapy. Int J Cardiol. 2018;269:165\u20139.","journal-title":"Int J Cardiol"},{"issue":"7","key":"2014_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/pace.13104","volume":"40","author":"E Bertaglia","year":"2017","unstructured":"Bertaglia E, Migliore F, Baritussio A, et al. Stricter criteria for left bundle branch block diagnosis do not improve response to CRT. Pacing Clin Electrophysiol. 2017;40(7):850\u20136.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"6","key":"2014_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40256-021-00503-8","volume":"21","author":"HA Blair","year":"2021","unstructured":"Blair HA. Dapagliflozin: a review in symptomatic heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2021;21(6):701\u201310.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"2014_CR22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"10254","key":"2014_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"36","key":"2014_CR24","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","volume":"42","author":"JP Curtain","year":"2021","unstructured":"Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727\u201338.","journal-title":"Eur Heart J"},{"issue":"1","key":"2014_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/europace\/euab177","volume":"24","author":"D Sfairopoulos","year":"2022","unstructured":"Sfairopoulos D, Zhang N, Wang Y, et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022;24(1):20\u201330.","journal-title":"Europace"},{"issue":"10","key":"2014_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/clc.22468","volume":"38","author":"J Yap","year":"2015","unstructured":"Yap J, Lim FY, Gao F, et al. Correlation of the New York Heart Association classification and the 6-minute walk distance: a systematic review. Clin Cardiol. 2015;38(10):621\u20138.","journal-title":"Clin Cardiol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-025-02014-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02014-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:50:58Z","timestamp":1757134258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-025-02014-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2014"],"URL":"https:\/\/doi.org\/10.1007\/s10840-025-02014-x","relation":{},"ISSN":["1572-8595"],"issn-type":[{"type":"electronic","value":"1572-8595"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the principles of the Helsinki Declaration and with the standards of Good Clinical Practice. The study was approved by the local ethics committee at Cardiology Research Institute (protocol No. 163 dated November 08, 2017). The majority of included patients were from a registered study (ClinicalTrials.gov, NCT03667989).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent for publication of clinical data was obtained from all the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}